Axsome Therapeutics, Inc.

Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO. The company combines marketed products with a pipeline aimed at psychiatric and neurological conditions where treatment options remain limited or inadequate. Its business model is centered on developing differentiated medicines, securing regulatory approvals, and commercializing them directly in the United States while also monetizing select assets through licensing. Axsome is still in a growth-and-investment phase, with meaningful revenue expansion but continued operating losses as it scales its commercial infrastructure and clinical pipeline.

−26,0 %

−28,7 %

+65,5 %

1.55

1.48

— Axsome Therapeutics, Inc.
%
Commercial CNS products92% Approved medicines sold in the U.S. for depression, sleep disorders, and migraine.
Royalty and licensing revenue1% Royalties from out-licensed SUNOSI sales in non-U.S. territories through Pharmanovia.
Pipeline and development programs7% Clinical-stage CNS candidates and lifecycle expansion programs that are not yet commercialized.

Axsome sells primarily to patients through the prescription drug channel, with demand driven by physicians treating...

  • U.S. prescription patientsprimary

    Patients diagnosed with depression, sleep disorders, or migraine who receive Axsome's branded therapies through physician prescriptions and pharmacy dispensing.

  • Prescribing physiciansprimary

    Psychiatrists, primary care physicians, sleep specialists, and neurologists who choose Axsome products based on efficacy, tolerability, and unmet need.

  • Payers and pharmacy benefit managersprimary

    Managed care organizations that determine formulary access, prior authorization, and patient affordability for the company's branded medicines.

  • Pharmanovia license partnersecondary

    The out-licensing partner for SUNOSI in certain territories, which commercializes the product and pays royalties and milestone-based consideration.

Axsome's commercial business is concentrated in the United States, where AUVELITY, SUNOSI, and SYMBRAVO are sold and...

  • •United States is the core commercial market for all three approved products
  • •Out-licensed SUNOSI territories generate royalty revenue through Pharmanovia
  • •Contract manufacturing is outsourced and subject to U.S. and foreign cGMP oversight
  • •Commercial execution is concentrated in the U.S. specialty prescription market
  • •International exposure is limited and mostly partnership-driven rather than direct sales

Axsome's strategy is to build a differentiated CNS franchise by commercializing approved products while advancing a...

01
Grow the commercial franchise for AUVELITY, SUNOSI, and SYMBRAVOshort-term

These are the company's current revenue engines and the main path to scale toward profitability.

02
Advance pipeline programs in CNS disordersmedium-term

Additional approvals would diversify revenue and reduce reliance on a small number of products.

03
Differentiate through proprietary drug design and formulationmedium-term

Novel mechanisms and delivery technologies are central to competing in crowded CNS markets.

Axsome remains exposed to the classic risks of a commercial-stage biopharma company: product concentration, regulatory...

high

Need for additional financing

The company has incurred significant losses and expects continued operating losses as it funds commercialization and development.

Scope
Could delay or reduce clinical programs and commercial expansion if capital is unavailable.
Materiality
high
high

Regulatory failure or delay for pipeline assets

Product candidates require FDA approval and can be rejected or delayed, as seen with the AXS-14 Refusal to File letter.

Scope
Pipeline value and future revenue growth depend on successful approvals.
Materiality
high
medium

Commercial concentration in a few products

Revenue is anchored by AUVELITY, SUNOSI, and SYMBRAVO, so any slowdown in one product can affect total growth.

Scope
Affects revenue growth, gross margin leverage, and operating leverage.
Materiality
high
medium

Intense CNS competition

The company competes against large pharmaceutical and biotechnology firms with established brands and resources.

Scope
Can pressure pricing, formulary access, and market share.
Materiality
high
medium

Manufacturing and supply-chain dependence

Axsome relies on a limited number of contract manufacturers and must meet cGMP requirements.

Scope
Could disrupt product availability or increase cost of goods.
Materiality
medium
Revenue recognition and quarterly volatility
Revenue and operating margin can swing with demand, channel inventory, and partner sales
Royalty revenue from Pharmanovia
Creates non-U.S. revenue exposure with variable timing and amount
Contingent consideration fair value
Can create non-cash gains or losses in the income statement
Intangible asset amortization and impairment
Affects operating expense and could trigger impairment charges if assumptions weaken
Debt and interest expense accounting
Impacts net loss and can obscure underlying operating performance

Axogen, Inc.

AXGN · Electromedical & Electrotherapeutic Apparatus

Clearside Biomedical, Inc.

CLSDQ · Pharmaceutical Preparations

Xenon Pharmaceuticals Inc.

XENE · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

SANGAMO THERAPEUTICS, INC

SGMOQ · Biological Products, (No Diagnostic Substances)

BioXcel Therapeutics, Inc.

BTAI · Pharmaceutical Preparations

: 11/08/2026